Three MTN studies – REACH, DELIVER, and B-PROTECTED – recently published critical new data on PrEP ring use among adolescent girls and young women (AGYW), pregnant individuals, and breastfeeding individuals in Africa. All studies offer compelling evidence that the ring is safe for use among these populations.
Continue Reading
Through oral PrEP, condoms, voluntary medical male circumcision, and antiretroviral treatment, USAID has helped to expand prevention options and access for all. Today, USAID continues to provide global leadership in the HIV response by expanding access to options with a new generation of HIV prevention products.
Continue Reading
This IAS 2023 session will review evidence from recent studies designed to inform CAB PrEP introduction in Asia; identify regional priorities for a CAB implementation science agenda; examine regional lessons from oral PrEP introduction and scale-up; highlight progress and lessons from preparing for CAB rollout in Africa; and introduce available policy and program planning tools and resources to help countries prepare for CAB rollout.
Continue Reading
As marketing for PrEP has evolved, we have seen a shift away from strategies we know don’t work: fear-based, stigma-reinforcing, HIV-centric, medicalized, and far-future focused. Yet we need to go a step further and analyze all the insights that form the backbone of our campaigns and our messages through a gender-transformative lens.
Continue Reading
We are excited to announce the launch of Catalyzing Access to New Prevention Products to Stop HIV (CATALYST), MOSAIC’s flagship product introduction study. CATALYST will provide and assess an enhanced service delivery package that includes oral PrEP, the PrEP ring, and injectable cabotegravir for PrEP.
Continue Reading
Demand for oral PrEP has been an issue. How can we do marketing differently with a multi-product PrEP portfolio? What do we want young women’s hearts to feel—and minds to think—about PrEP? These question about the positioning of PrEP are central to its branding as a multi-product category.
Continue Reading
As new PrEP products move out of clinical trials and toward market entry, implementation research has a pivotal role to play in guiding the introduction and scale-up of these new products in real-world service delivery settings.
Continue Reading
New products, including the dapivirine vaginal ring and injectable cabotegravir, have been approved in several countries, and more biomedical prevention products are in development. As the catalog of HIV prevention products expands, so too does the conversation about the importance of upholding choice to optimize the benefits for potential PrEP users.
Continue Reading
The future of HIV prevention is here. Injectable cabotegravir (CAB) is the most effective, longest-acting option for avoiding the virus. Until now, pre-exposure prophylaxis (or PrEP) medicine taken to prevent HIV has only been available as an oral pill that must be taken daily. CAB needs to be injected only once every two months.
Continue Reading
As we move toward a multi-product HIV prevention market, adolescent girls and young women must be empowered to choose an HIV prevention product that meets their needs.
Continue Reading